Pathobiochemistry of inhibin A and its use in the screening of congenital developmental defects.

Česká verzia

Authors: J. Loucký ^1,2; R. Průša ²
Authors place of work: Vaše laboratoře s. r. o., U Lomu 638, Zlín, 760 01 ¹; Ústav lékařské chemie a klinické biochemie, 2. LF UK a FN Motol, V úvalu 84, Praha 5, 150 06 ²
Published in the journal: Klin. Biochem. Metab., 28, 2020, No. 1, p. 5-10

Summary

Inhibins are glycoproteins which belong to the transforming growth factor beta family (TGF-β), which contains more than 60 proteins as well as activins, which are structurally similar but differ in terms of function. Inhibins in women are formed in the ovarian granulosa cells, inhibin A is also produced during pregnancy by the yellow body and the placenta. Inhibins play an important role in the regulation of folliculogenesis and oocyte maturation. In males, inhibins are predominantly produced in the testicular Sertoli cells and in a smaller quantity also in the Leydig cells. Their synthesis is stimulated by the effects of androgens but is primarily regulated by spermatogenesis. Currently, it is also clear that the function of inhibins include a much broader spectrum of effects, which are not only related to the reproductive system. In pregnancy, the source of inhibin A is the yellow body and later the placenta. Inhibin (and also activin) have a paracrine and autocrine function in the human placenta and locally affect the production of hormones in the placenta, cellular immunity, cell growth and differentiation of the placenta and embryo. Placental cytotrophoblast and syncytiotrophoblast secrete inhibin A, which inhibits the placental secretion hCG and progesterone. In some cases, biochemical markers that are produced by the placenta during pregnancy are used as markers for Down syndrome screening. It has been discovered that an increase in the level of inhibin A is to some degree associated with the presence of Down syndrome and may be used in combination with other biochemical markers produced by the fetoplacental unit as a biochemical screening marker.

Keywords:

inhibin A – Down syndrome – prenatal screening

Zdroje

1. Mason, A. J., Hayflick, J. S., Ling, N., Esch, F., Ueno, N., Ying, S.-Y., Guillemin, R., Niall, H. and Seeburg, P. H. Complementary DNA sequences of ovarian follicular fluid inhibin show precursor structure and homology with transforming growth factor-β. Nature 1985, 318(6047), p. 659–663.

2. McCullagh, D. R. Dual endocrine activity of the testes. Science (New York, N.Y.), 1932, 76(1957), p. 19–20.

3. De Jong, F. H. and Sharpe, R. M. Evidence for inhibin-like activity in bovine follicular fluid. Nature, 1976, 263(5572), p. 71–72.

4. Ledger, W. L. and Muttukrishna, S. Inhibin, Activin and Follistatin in Human Reproductive Physiology. Edi-ted by S. Muttukrishna. London: Imperial College Press, 2014

5. Woodruff, T. K., Lyon, R. J., Hansen, S. E., Rice, G. C. and Mather, J. P. Inhibin and activin locally regulate rat ovarian folliculogenesis. Endocrinology, 1990, 127(6), p. 3196–3205.

6. Gupta, M. K. and Chia, S.-Y. Ovarian hormones: structure, biosynthesis, function, mechanism of action, and laboratory diagnosis. in Clinical Reproductive Medicine and Surgery, New York, NY, 2013, p. 1–30.

7. Kiserud, C. E., Magelssen, H., Fedorcsak, P. and Fosså, S. D. Gonadal function after cancer treatment in adult men. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke, 2008, 128(4), p. 461–465.

8. Good, T., Weber, P. S., Ireland, J. L., Pulaski, J., Padmanabhan, V., Schneyer, A. L., Lambert-Messerlian, G., Ghosh, B. R., Miller, W. L. and Groome, N. Isolation of nine different biologically and immunologically active molecular variants of bovine follicular inhibin. Biology of reproduction, 1995, 53(6), p. 1478–88.

9. Robertson, D., Burger, H. G., Sullivan, J., Cahir, N., Groome, N., Poncelet, E., Franchimont, P., Woodruff, T. and Mather, J. P. Biological and immunological characterization of inhibin forms in human plasma. Journal of Clinical Endocrinology and Metabolism, 1996, 81(2), p. 669–676.

10. Sugino, K., Kurosawa, N., Nakamura, T., Takio, K., Shimasaki, S., Ling, N., Titani, K. and Sugino, H. Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell. The Journal of biological chemistry, 1993, 268(21), p. 15579–87.

11. Barton, D. E., Yang-Feng, T. L., Mason, A. J., Seeburg, P. H. and Francke U. Mapping of genes for inhi-bin subunits α, βa, and βB on human and mouse chromosomes and studies of jsd mice. Genomics, 1989, 5(1), p. 91–99.

12. Mason, A. J., Niall, H. D. and Seeburg, P. H. Structure of two human ovarian inhibins. Biochem. Biophys. Res. Commun., 1986, 135, p. 957–964.

13. Baird, D. T. and Smith, K. B. Inhibin and related peptides in the regulation of reproduction. Oxford reviews of reproductive biology, 1993, 15, p. 191–232.

14. Wald, N. J., Densem, J. W., George, L., Muttukrishna, S. and Knight, P. G. Prenatal screening for Down’s syndrome using inhibin-A as a serum marker. Prenatal diagnosis, 1996, 16(2), p. 143–53.

15. Makanji, Y., Temple-Smith, P. D., Walton, K. L., Harrison, C. A. and Robertson, D. M. Inhibin b is a more potent suppressor of rat follicle-stimulating hormone release than inhibin a in vitro and in vivo. Endocrinology, 2009, 150(10), p. 4784–4793.

16. Woodruff, T. K., Krummen, L. A., Chen, S. A., Lyon, R., Hansen, S. E., DeGuzman, G., Covello, R., Mather, J. and Cossum, P. Pharmacokinetic profile of recombinant human (rh) inhibin A and activin A in the immature rat. II. tissue distribution of [125i]rh-inhibin A and [125i]rh-activin A in immature female and male rats. Endocrinology, 1993b, 132(2), p. 725–34.

17. Stenvers, K. L. and Findlay, J. K. Inhibins: from reproductive hormones to tumor suppressors. Trends in endocrinology and metabolism. Elsevier, 2010, 21(3), p. 174–80.

18. Doherty, G. J. and McMahon, H. T. Mechanisms of endocytosis. Annual review of biochemistry, 2009, 78, p. 857–902.

19. Barth, D. G. and Miyuki, S. Intracellular trafficking. WormBook, ed. The C. Elegans Research Community, 2006, [online] Available at: http://www.wormbook.org/chapters/www.intracellulartrafficking/intracellulartrafficking.html [Accessed: 28-11-2018].

20. Muttukrishna, S., George, L., Fowler, P. A., Groome, N. P. and Knight, P. G. Measurement of serum concentrations of inhibin-A (alpha-beta A dimer) during human pregnancy. Clinical endokrinology, 1995, 42(4), p. 391–7.

21. Fowler, P., Evans, L. W., Groome, N. P., Templeton, A. and Knight, P. G. A longitudinal study of maternal serum inhibin-a, inhibin-b, activin-a, activin-ab, pro-alphac and follistatin during pregnancy. Human reproduction (Oxford, England), 1998, 13(12), p. 3530–6.

22. McLachlan, R. I., Healy, D. L., Robertson, D. M., Burger, H. G. and de Kretser, D. M. Circulating immunoactive inhibin in the luteal phase and early gestation of women undergoing ovulation induction. Fertility and sterility, 1987, 48(6), p. 1001–5.

23. Petraglia, F., Sawchenko, P., Lim, T., Rivier, J. and Vale, W. Localization, secretion, and action of inhibin in human placenta. Science (New York, N.Y.), 1987, 237(4811), p. 187–189.

24. Leck, I. and Wald, N. J. Antenatal and neonatal scree-ning. Oxford: Oxford University Press, 2000.

25. Palomaki, G. E., Lambert-Messerlian, G. M. and Canick, J. A. A summary analysis of Down syndrome markers in the late first trimester. Advances in clinical chemistry, 2007, 43, p. 177–210.

26. Verlohren, S., Herraiz, I., Lapaire, O., et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am. J Obstet. Gynecol., 2012, 206(1), 58.e1-8

27. Wald, N. J., Bestwick, J. P., Huttly, W. J. Improvements in antenatal screening for Down’s syndrome. J Med Screen, 2013, (20), p. 7–14

28. Norton, M. E., Jacobsson, B., Swamy, G. K, Laurent, L. C., Ranzini, A. C., Brar, H., Tomlinson, M. W., Pereira, L., Spitz, J. L., Hollemon, D., Cuckle, H., Musci, T. J., Wapner, R. J. Cell-free DNA Analysis for Noninvasive Examination of Trisomy: The New England Journal of Medicine, 2015, 372(17), p. 1589-1597

29. Macintosh, M. C., Wald, N. J., Chard, T., Hansen, J., Mikkelsen, M., Therkelsen, A. J., Petersen, G. B., Lundsteen, C. Selective miscarriage of Down’s syndrome fetuses in women aged 35 years and older. Br J Obstet. Gynaecol., 1995, 102(10), p. 798-801.

30. Loucky, J., Belaskova, S., Prusa, R., Kotaska, K. The effect of inhibin A on prenatal screening results for down syndrome in the high risk Czech pregnant women, Clin. Lab., 2019, 65, p. 707-716

31. Wald, N. J., Rodeck, C., Hackshaw, A. K. and Rudnicka, A. SURUSS in perspective. BJOG: An International Journal of Obstetrics and Gynaecology, 2004, 111(6), p. 521–531.

32. Malone, F. D., Canick, J. A., Ball, R. H., Nyberg, D. A., Comstock, C. H., Bukowski, R., Berkowitz, R. L., Gross, S. J., Dugoff, L., Craigo, S. D., Timor-Tritsch, I. E., Carr, S. R., Wolfe, H. M., Dukes, K., Bianchi, D. W., Rudnicka, A. R., Hackshaw, A. K., Lambert-Messerlian, G., Wald, N. J. et al. First-trimester or se-cond-trimester screening, or both, for Down’s syndrome. The New England journal of medicine, 2005, 353(19), p. 2001–11.

33. Palomaki, G. E., Kloza, E. M., Lambert-Messerlian, G. M., Haddow, J. E., Neveux, L. M., Ehrich, M., van den Boom, D., Bombard, A. T., Deciu, C., Grody, W. W., Nelson, S. F. and Canick, J. A. DNA sequencing of maternal plasma to detect down syndrome: an international clinical validation study. Genetics in medicine: official journal of the American College of Medical Gene-tics, 2011, 13(11), p. 913–20.

34. Wald, N. J. Prenatal reflex dna screening for trisomy 21, 18 and 13. Expert review of molecular diagnostics.: Taylor & Francis, 2018, 18(5), p. 399–401.

35. Registr laboratoří zabývajících se screeningem VVV. (2018, December 21). Retrieved from: http://www1.lf1.cuni.cz/~dbezd/